Pharma CEO & MD Executive Search in India — Listed Generics, MNC, API / CDMO and Biologics

A listed generics CEO at Indian-headquartered scale runs the most operationally complex CEO role in the sector. The US business is typically driven by complex-generics, 505(b)(2), injectables, and respiratory / ophthalmic / dermatology portfolios — each with distinct regulatory pathways. EU submissions run through decentralised and mutual-recognition procedures with national variations. Emerging markets require country-by-country product registration and commercial distribution partnerships. Domestic India runs on chronic and acute therapy rotations with MR-led promotion at scale. The CEO orchestrates the portfolio-geography-regulatory matrix alongside the Chief Scientific Officer, Quality Head, and Global Commercial Head.

• •US business architecture — ANDA filings cadence, complex-generics and speciality tilt, FDA inspection readiness across all manufacturing sites.
• •EU architecture — MAA submissions, pharmacovigilance obligations, post-Brexit UK MHRA separation.
• •EM architecture — country-regulator relationships, local partner selection, currency and pricing exposure.
• •India architecture — chronic and acute therapy portfolio, field-force productivity (MR : product ratio), chemist-pharmacy relationships, and NLEM / price-control exposure.
• •Quality architecture — USFDA inspection readiness, Warning Letter remediation if applicable, quality-management-system maturity across sites.

An MNC India CEO runs the India-listed or unlisted subsidiary P&L of a global pharma parent with focus on the India therapy portfolio, CDSCO regulatory interaction, local manufacturing (where present), and commercial distribution. The CEO reports to a Global or Regional Head and carries P&L accountability within a global operating framework. Common therapy anchors include diabetology, cardiology, oncology, immunology, and vaccines. The role requires deep India-commercial literacy (field-force scaling, medical-affairs interface, KOL engagement) combined with multinational-operating-discipline (Board reporting, compliance, CSR). India MNC pharma CEO packages are capped by parent-company global frameworks and typically trail listed-Indian-generics packages at comparable scale.

• •Regulatory posture — named USFDA, EMA, MHRA, CDSCO inspection track record; Form-483 / Warning Letter remediation experience.
• •Portfolio architecture — multi-market, multi-therapy portfolio construction with clear complex-generics / speciality / biosimilar tilt.
• •Quality and manufacturing discipline — site-level quality-management-system maturity and capex-cycle-aware manufacturing strategy.
• •R&D / pipeline architecture — ANDA / MAA / BLA pipeline strength and translation from research to registration to revenue.
• •Commercial architecture — US commercial partnership, EU national go-to-market, EM partner selection, India field-force productivity.
• •M&A and in-licensing track record — named transactions owned with measured outcomes.
• •Leadership bench — Chief Scientific Officer, Global Quality Head, Regional Commercial Heads, CFO the candidate has built and retained.
• •Board / investor cadence — sell-side analyst fluency, Chair and NRC working relationship architecture.

1. 1.Mandate brief with the Chair and lead sponsor — 90 minutes identifying which of four CEO contexts applies.
2. 2.Persona engineering — competency matrix weighted by context with explicit regulatory-posture weighting.
3. 3.Sector mapping — Gladwin's live pharma CEO map of ~100 candidates segmented by context, therapy depth, and regulatory track.
4. 4.Longlist research — 20–30 candidates with three-page profiles covering multi-market portfolio scale, regulatory track record, and R&D pipeline leadership.
5. 5.Discreet partner-led approach — phone-first contact, sanitised mandate brief, NDAs before detail shared.
6. 6.Pre-qualification — 90-minute partner interviews on regulatory philosophy, portfolio architecture, and first-180-days mandate plan.
7. 7.Competency assessment — structured scoring plus a written regulatory-remediation or portfolio-architecture vignette on a sanitised context.
8. 8.Reference triangulation — minimum six references including Chair / lead sponsor, peer CXO, Chief Scientific Officer or Quality Head from prior role, and at least one US or EU commercial partner.
9. 9.Shortlist — three candidates to the NRC / Board with comparative scoring and a detailed regulatory-posture memo.
10. 10.Offer structuring (including deferred variable and RSU / ESOP LTI design), notice-period management, and a 100-day integration plan covering quality-leader engagement, site-tour cadence, and commercial-partner review.